Skip to main content

Diabetes Mellitus: Its Goals Of Therapy!

 GOAL OF THERPY

The goals of treatment of DM includes;

  • Reducing, controlling and managing long-term microvascular, macrovascular and neuropaathic complications.
  • Preserving beta cell function.
  • Preventing acute complications from increased Blood glucosel level.
  • Minimizing hypoglycemic episodes.
  • Maintaining patient quality of life.


--Two landmark trials, THE DIABETES CONTROL AND COMPLICATION TRIAL (DCCT) and THE UNITED KINGDOM PROSPECTIVE DIABETES STUDY(UKPDS), showed that lowering blood glucose levels decreased the risk of developing chronic complications.

--A near normal blood glucose level can be achieved with appropriate patient education, lifestyle modification and medications.

--Proper care of DM requires goal setting and assessment for glycemic control, self-monitoring of blood glucose (SMBG) monitoring of blood glucose pressure, and lipid levels, regular monitoring for the development of complications, dietary and exercise lifestyle modifications and proper medication use 

Proper care of DM requires goal setting and assessment of Glycemic control by; 

  • Monitoring daily blood glucose levels.
  • A1c monitoring 
  • Estimated Average Glucose values (eAG) monitoring.
  • Blood pressure.
  • Lipid levels.


                         1.MONITORING OF BLOOD GLUCOSE LEVELS

                      1. By SMBG.                                                       2. By Glucose sensors.

  • The ADA premeal plasma glucose levels goals are 70-130 mg/dL and peak post-prandial plasma glucose level goals are <180mg/dL. 
  • The American Association of Clinical Endocrinologists (AACE) supports tighter SMBG controls with premeal glucose level goals of < 110mg/dL. and post-prandial glucose level goals of < 140mg/dL.
  • For patients using multiple daily insulin injections or Insulin pumps therapy, the ADA recommends that SMBG be performed at least 3 times daily.

a) SMBG: It is a standard method that enables patient to obtain their current blood glucose levels at any time and is relatively inexpensive.

  • Each patient should be educated regarding how often and when to perform SMBG. 
  •  Typically, in SMBG, a drop of blood is placed on the blood sample size required to as small as 0.3 micrometers, provided the capability of alternate site testing and allowed for the delivery of readings in as few as 5 seconds. 

b) Glucose sensors: Several continuous glucose sensors are now available that works with or independently of insulin pumps. These monitors provide blood glucose readings, primarily through the interstitial fluid (ISF). 

  • A small sterile disposable glucose sensing device called a SENSOR is inserted into the subcutaneous tissues. The sensor then measures the change in glucose in ISF, and sends the information to a monitor, which stores the results.

 2.MONITORING OF HAEMOGLOBIN A1c:

Glucose interacts spontaneously with Hb in RBCs to form glycated derivatives. The most prevalent derivative is A1c because Hb has a life span of approx. 3 months, level of A1c provide a marker reflecting the average glucose levels over this time frame.


  • The ADA goals for persons with DM is less than 7% whereas AACE supports a goal of less than or equal to 6.5% 
  • Testing A1c levels should occur at least twice a year for patients who are meeting treatment goals and 4 times for patients who are not meeting goals 

3.ESTIMATED AVERAGE GLUCOSE eAG:

Estimated Average Glucose is used to correlate A1c values with readings that patients obtain from their home glucose monitors. 
  • The equation to convert from A1c to eAG is.
                                                   eAG(mg/dL) = 28.7*A1c- 46.7 
  • The goal for eAG is 154mg/dL which corresponds with an A1c of less than 7%.
  •  In standardized assay, a 1% rise in A1c translates into 35mg/dL increase in mean glucose.

4.KETONE MONITORING URINE AND BLOOD KETONE TESTING

  • It is important in people with T1DM, in pregnancy with pre-existing diabetes and in GDM. 
  • People with T2DM may have positive ketones and develop into Diabetic ketoacidosis if they are ill.
  • When there is a lack of insulin, peripheral tissues cannot take up and store glucose. this causes the body to think it is starving and because of excessive lipolysis, ketones, primarily Beta-hydroxybutyric acid and aceto-acetic acid, are produced as by-product of free fatty acids metabolism in liver.
  • Glucose and Ketones are osmotically active and when an excessive amount of ketones is formed, the body gets rid of them through urine, leading to dehydration. 
  • Patients with T1DM should test for ketones during acute illness or stress or when blood glucose levels are consistently elevated above 300mg/dL 
  • Women with pre-existing diabetes before pregnancy or with GDM should check ketones using their first morning urine sample or with any symptoms of Diabetic ketoacidosis such as nausea, vomiting or abdominal pain are present
  • Blood ketone testing methods that quantify Beta-hydroxybutyric acid are available and are a preferred way to diagnose and monitor DKA. 

Comments

Popular posts from this blog

Diabetes Mellitus: Types!

TYPES OF DIABETES MELLITUS 1. TYPE1 DM Type 1 DM is usually diagnosed before age 30 years, but it can develop at any age. T1DM is an autoimmune disease in which insulin producing B-cells are destroyed. The presence of Human Leucocyte Antigens (HLAs ) is associated with the development of T1DM. In addition, these individuals often develop Islet cell antibodies , Insulin Autoantibodies or Glutamic Acid decarboxylase autoantibodies . At the time of development of diagnosis of T1DM, it is usually believed that most of the patients have 80-90%loss of beta cells. The remaining beta cells function at the diagnosis creates a " HONEYMOON PERIOD" during which the blood glucose levels are easier to control, and smaller amounts of insulin are required. after this, the remaining beta cells function is completely lost, and the patients become completely deficient of insulin and hence require exogenous insulin.  2. TYPE1.5 DM:  Also referred as Latent autoimmune diabetes in Adults (LAD)

Diabetes Mellitus: Pharmacotherapy- Gliptins and a-Glycoside Inhibitors!

  PHARMACOTHERAPY:  Medications classifications include:  Sulfonyl Urea's Nonsylfonylurea Secretagogues (a-Glinides) Biguanides Thiazolidinediones a-Glucosidase Inhibitors Dipeptidyl Peptidase-4 Inhibitors (Gliptins) Sodium-glucose co-transporter (SGLT) Inhibitors  Central-Acting Dopamine Agonists Bile Acid Sequestrants Insulin therapy 5. a-GLUCOSIDASE INHIBITORS Acarbose and Miglitol are a-glucosidase inhibitors currently approved in the United States. Mechanism of Action: An enzyme that is along the brush border of the intestine cells called a-glucosidase; breaks down the complex carbohydrates into simple sugars, resulting in absorption. The a-glucosidase inhibitors work by delaying the absorption of carbohydrates from the intestinal tract, which reduces the rise in postprandial glucose levels. Therapy: As a monotherapy , a-glucosidase inhibitors primarily reduce post-prandial glucose excursions.  Clinical Use: FPG concentrations have been decreased by 40-50mg/dL and A1c level

GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD)!

MANAGEMENT OF GASTRO-ESOPHAGEAL REFLUX DISEASE  "GERD refers to the endoscopically determined esophagitis or endoscopy-negative reflux disease" . "GERD is the term used to describe any symptomatic clinical condition or histopathological alteration resulting from episodes of reflux of acid, pepsin and occasionally, bile into the esophagus from the stomach". Patients with uninvestigated "reflux-like" symptoms should be managed as patients with uninvestigated dyspepsia. There is currently no evidence that H.pylori should be investigated in patients with GERD. Symptoms: Heartburn is the characteristic symptom of GERD. Acid regurgitation Dysphagia Belching Upper abdominal discomfort Bloating and postprandial fullness Chest pain Hoarseness Cough Complications include: Esophageal ulceration Formation of specialized columnar-lined esophagus at the gastro-esophageal junction known as Barretts Esophagus . Mechanism of Acid Reflux: The mechanism of acid reflux is mu